PTCTPTC Therapeutics, Inc.

$5B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M+111.2% YoY

Gross Profit

$53M94.6% margin

Operating Income

-$17M-29.9% margin

Net Income

-$19M-34.4% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-28.2%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$379M

Total Liabilities

$229M

Stockholders' Equity

$150M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$27M	+111.2%
Gross Profit	$53M	$27M	+100.0%
Operating Income	-$17M	-$26M	+36.5%
Net Income	-$19M	-$29M	+33.7%

Revenue Segments

Licensing And Collaboration Agreement

$100,000100%

PTCT Q1 2018 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena